Vera Therapeutics (NASDAQ:VERA) stock up; Trutakna approval shifts attention to Q3 kidney data
Vera Therapeutics, Inc. finished up 7.05% at $42.96 on Tuesday after U.S. regulators approved Trutakna. The bigger investor focus was on the size of the bid. With 71.78 million shares outstanding from Google Finance and a $2.83 move on the day, that comes out to roughly $203 million more in equity value added. That’s around a third of Vera’s last reported cash, and not a big reset for a $3.08 billion biotech that’s now swapped FDA risk for launch risk.
